Efficacy of Neoadjuvant Chemotherapy Regimens Prior to Resection of Colorectal Liver Metastases by Datko, Farrah Mikhail
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
2-11-2008
Efficacy of Neoadjuvant Chemotherapy Regimens
Prior to Resection of Colorectal Liver Metastases
Farrah Mikhail Datko
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Datko, Farrah Mikhail, "Efficacy of Neoadjuvant Chemotherapy Regimens Prior to Resection of Colorectal Liver Metastases" (2008).
Yale Medicine Thesis Digital Library. 318.
http://elischolar.library.yale.edu/ymtdl/318
 
 
 
 
 
EFFICACY OF NEOADJUVANT 
CHEMOTHERAPY REGIMENS PRIOR TO 
RESECTION OF COLORECTAL LIVER 
METASTASES 
 
 
 
 
 
 
 
A Thesis Submitted to the 
Yale University School of Medicine 
in Partial Fulfillment of the Requirements for the 
Degree of Doctor of Medicine 
 
 
 
 
 
 
 
 
 
 
 
 
 
Farrah Mikhail Datko  
2007 
 2
EFFICACY OF NEOADJUVANT CHEMOTHERPAY REGIMENS PRIOR TO 
RESECTION OF COLORECTAL LIVER METASTASES. 
Farrah M. Datko (Sponsored by M. Wasif Saif). Yale Cancer Center, Department of 
Internal Medicine, Yale University School of Medicine, New Haven, CT. 
 
 While new treatments for metastatic colorectal cancer continue to be developed, 
the ideal neoadjuvant regimen prior to resection of liver metastases is still unknown.  The 
primary goal of this study was to compare disease-free survival outcomes in patients who 
received oxaliplatin- or irinotecan-based neoadjuvant chemotherapy regimens prior to 
resection of colorectal liver metastases. 
 A retrospective chart review was performed of all 27 patients who underwent 
liver resection of colorectal cancer metastases at Yale-New Haven Hospital between 
January 2003 and December 2005.  Records were reviewed for details of initial 
diagnosis, treatment regimen(s) prior to resection of hepatic metastases, results of 
surgical liver resection, adjuvant treatment after liver resection, post-operative disease 
recurrence and overall survival.  Median disease-free survival calculations were based on 
survival curves drawn according to Kaplan-Meier methods. 
 Out of 15 patients with at least one year of follow-up, six were treated with 
neoadjuvant FOLFOX prior to liver resection, three with first-line FOLFOX followed by 
second-line FOLFIRI, two with FOLFIRI, one with IFL, and three patients had no 
neoadjuvant chemotherapy.  Median disease-free survival was 15.5 months in patients 
treated with neoadjuvant FOLFOX, 16.3 months in patients treated with first-line 
FOLFOX followed by second-line FOLFIRI, 16.3 months in patients treated with 
irinotecan-based neoadjuvant therapy, and was not reached in the group who did not 
receive any neoadjuvant treatment (p=0.84).  Actual one-year disease-free survival rate 
was 67% regardless of neoadjuvant treatment group.  The sample size was too small to 
determine which patient, tumor, and treatment variables were associated with disease 
recurrence. 
 The majority of patients undergoing liver resection of colorectal metastases at 
Yale-New Haven Hospital in recent years were treated with neoadjuvant FOLFOX.  
Median disease-free survival and actual one-year disease-free survival was almost 
identical among patients receiving FOLFOX, irinotecan-based regimens, or first-line 
FOLFOX followed by second-line FOLFIRI, although analysis was limited by a small 
sample size.  Larger prospective trials are needed to compare oxaliplatin- and irinotecan-
based neoadjuvant chemotherapy regimens for patients with either resectable or 
unresectable colorectal hepatic metastases.
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INTRODUCTION 
 
 Colorectal cancer is the third leading cause of cancer deaths in the United States, 
estimated at 55,000 in 2006 [1].  Nearly one million new cases are diagnosed every year 
around the world, making colorectal cancer the third most prevalent type of cancer 
worldwide.  In the United States, one in 17 men (5.9%) and one in 18 women (5.5%) will 
be diagnosed with colorectal cancer during their lifetime [2].   
 The liver is the most common site of colorectal metastases.  Over half of all 
patients with colorectal cancer will have metastatic disease to the liver either at diagnosis 
(15-25%) or during the course of their disease (another 35-45%) [3].  In fact, many of 
these patients will have liver-only metastases.  This predilection is largely due to the 
portal venous system, which drains blood directly from colorectal capillary beds to the 
liver.  Colorectal cancer cells that have penetrated a blood vessel at the primary tumor 
site will encounter the liver before any other organ, where they are most likely to lodge 
and grow into a new focus.  This is in contrast to liver metastases from other primary 
tumors (e.g., breast, lung, melanoma), which are generally an indication of much more 
widespread disease.  In these cases, surgical resection of liver metastases is considered 
futile.  Resection of colorectal metastases to the liver, however, can be curative. 
 
Surgical resection of colorectal metastases to the liver 
 Even in the absence of prospective analysis, it is now well-established that hepatic 
resection of colorectal metastases is essential for any chance of long-term survival.  
Several studies have retrospectively compared survival outcomes after surgical resection 
of colorectal liver metastases with chemotherapy alone.  In 1990, Scheele et al. looked at 
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a large cohort of patients with colorectal liver metastases treated between 1960 and 1987.  
There were no 5-year survivors out of 921 patients with unresectable disease.  In 
comparison, the five-year survival rate was 31% for the group of 226 resected patients 
[4].  A later update in 469 resected patients reported a five-year survival rate of 39% [5].  
Since patients with resectable disease often have lower tumor burden and thus more 
favorable prognosis than those considered unresectable, this study also looked at patients 
with potentially resectable disease who did not undergo surgery for various reasons.  This 
subgroup of 62 patients also failed to reach 5-year survival [4].  More recently, Kato et al. 
analyzed a cohort of patients treated between 1992 and 1996, demonstrating a 5-year 
survival rate of 3.4% for unresected patients (n=178) compared to 32.9% for patients 
undergoing hepatectomy for hepatic metastases (n=585) [6].  An epidemiologic study of 
patients with metachronous colorectal liver metastases between 1976 and 2000 reported a 
5-year survival rate of 3.1% in pts receiving chemotherapy alone (n=82) and 29.0% in pts 
undergoing resection (n=79) [7].  Additional studies that have reported five-year survival 
rates in large cohorts of patients after hepatic resection include Nordlinger et al (28%, 
n=1568), Fong et al. (37%, n=1001), and Figueras et al. (36%, n=235) [8-10].  In 
summary, historical five-year overall survival with chemotherapy alone has been rare, 
compared to survival rates in the range of 28-39% after resection of liver metastases.  
Indeed, with such convincing data, it would be very difficult to design a prospective 
study which randomizes patients to receive chemotherapy only, as offering what is 
considered palliative treatment when a curative option exists would be considered 
unethical. 
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 It is important to note that the patients included in the above studies were treated 
before recent advances in chemotherapeutic agents.  Long-term survival in patients 
receiving newer and more effective therapeutics are clearly improving but just now being 
published.  With the adjuvant use of these newer agents, 5-year survival rates after 
resection of colorectal liver metastases are now in the range of 50-60% [11, 12].  
Although unlikely, it is possible that treatment with newer combination chemotherapy 
alone can result in similar 5-year survival rates.  This data will be difficult to ascertain, 
however, as all patients who become resectable must now be considered for surgery.  For 
now, we only have scattered accounts of long-term remission in patients who declined 
surgery [13] or who responded so dramatically to neoadjuvant chemotherapy that one or 
more liver metastases could not be found intraoperatively for resection [14]. 
 
Defining resectability 
 Patients must be carefully selected for resection of colorectal liver metastases.  
Only complete tumor removal (R0 resection) results in a survival benefit.  In contrast, 
patients who undergo resections with positive microscopic margins (R1 resections) or 
grossly positive margins (R2 resections) have survival outcomes comparable to 
unresected patients [5].  Therefore, the goal is to maximize the rate of complete 
resections while avoiding morbidity from unnecessary surgeries. 
 The definition of resectability has evolved over time and still remains to be 
definitively established.  In the 1970s and 1980s, resection was often limited to selected 
younger patients with only one liver metastasis.  With accumulating evidence that 
surgical resection offered much improved long-term survival, the criteria for resectability 
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began to expand.  Nevertheless, approximately 80% of patients have hepatic metastases 
considered unresectable at the time of presentation, due to a combination of factors 
including tumor size, number, extent and location [15]. 
 Two landmark studies published in 1986 established the first contraindications to 
resection of colorectal liver metastases.  The first, by Ekberg et al, analyzed factors 
influencing survival after liver resection, while the second, by Hughes et al, sought to 
determine which variables increased the likelihood of recurrence after resection [16, 17]. 
From these and similar studies, the classic contraindications to resection became the 
following: four or more liver metastases, metastasis diameter >5cm, bilobar metastases, 
the presence of extrahepatic disease, and proximity to vital structures that would preclude 
resection margins of at least 1cm.  Resections were preferably offered to patients with 1-3 
unilobar metastases presenting metachronously (i.e., not present at diagnosis of the 
primary colorectal tumor). 
 Two decades later, these contraindications are no longer valid.  Patient with 
resection of multiple (≥4) liver metastases have been shown to have favorable outcomes 
after surgery (five-year survival rate 33%, n=98) [18], as well as patients with resectable 
extrahepatic disease (five-year survival rate 28%, n=84) [19].  Although wide resection 
margins remain the goal, even patients who can be resected with minimal margins should 
be offered surgery [20, 21].  A recent retrospective analysis demonstrated that patients 
with large metastases (>8cm) also benefit from surgery, with 5-year survival rates of 38% 
(n=88) compared with 42% in those with smaller metastases (n=396, not a statistically 
significant difference, p=0.303) [22]. 
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 The most up to date criteria for resectability were established during the American 
Hepato-Pancreato-Biliary Association consensus conference early 2006 and outlined in 
the 2005 OncoSurge therapeutic decision model [20, 23].  Using existing evidence and an 
expert panel, the following absolute contraindications to resection were defined:  
“unresectable extrahepatic disease (such as peritoneal carcinomatosis, multifocal lung 
metastases, and distant lymph nodes in the preaortic and celiac axis N2 nodal basin for 
the liver, bone, or brain metastases), extensive liver involvement (more than six liver 
segments involved, >70% liver invasion or all three hepatic veins involved), major liver 
insufficiency or Child B or C liver cirrhosis with complications, and patients unfit for or 
declining surgery” [23]. 
 While each patient must still be evaluated individually, it is important to have 
established criteria of resectability and non-resectability for comparative analysis across 
the literature.  With such a high percentage of patients considered unresectable at initial 
presentation, one of the goals of neoadjuvant chemotherapy is to shrink tumors to the 
point of resectability.  Unfortunately, the majority of studies evaluating the efficacy of 
various neoadjuvant regimens in this regard use considerably different definitions of 
resectability or fail to define any criteria at all [13]. 
 
Oxaliplatin and irinotecan in advanced colorectal cancer 
 For decades, the mainstay of chemotherapy in metastatic colorectal cancer has 
been the thymidylate synthase inhibitor flourouracil (5-FU), given in combination with 
the potentiator folinic acid (leucovorin, LV).  Although randomized trials demonstrated 
improved overall survival and quality of life compared to best supportive care, actual 
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response rates were disappointingly low (18-44%), with a median overall survival of just 
11-15 months in eight randomized trials [24].  With few new drug prospects, research 
focused on comparing various treatment delivery schedules in order to minimize toxicity 
while optimizing survival outcomes.  For example, one large meta-analysis demonstrated 
that continuous intravenous infusion of 5-FU is superior to intravenous bolus [25].  More 
recently, capecitabine, an oral prodrug of 5-FU, has been shown to be as effective as 
bolus 5-FU/LV in a phase III trial of 1987 patients with advanced colorectal cancer [26].  
The oral prodrug capecitabine is associated with less neutropenia but an increased 
incidence of hand-foot syndrome. 
 After years of disappointing outcomes in patients treated with 5-FU/LV alone, 
there now are two newer cytotoxic agents which have substantially improved prognosis 
in patients with advanced colorectal cancer when given in combination with 5-FU/LV.  
The first of these is oxaliplatin, a third generation platinum analog, which works 
synergistically with infusional 5-FU/LV in the FOLFOX regimen.  One phase III trial 
randomized 420 patients with previously untreated metastatic colorectal cancer to receive 
5-FU/LV with or without oxaliplatin.  The addition of oxaliplatin resulted in better 
median progression-free survival (9.0 vs. 6.2 months, p=0.0003) and superior response 
rates (50.7% vs. 22.3%, p=0.0001), although overall survival did not reach statistical 
significance (16.2 vs. 14.7 months, p=0.12) [27].  In the MOSAIC trial, 1347 patients 
with stage III colon cancer were randomized to receive six months of adjuvant infusional 
5-FU/LV with or without oxaliplatin.  Patients in the oxaliplatin-containing arm 
demonstrated a statistically significant improvement in disease-free survival at three 
years (72.2% with oxaliplatin vs. 65.3% without oxaliplatin, hazard ratio for relapse 0.76 
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with 95%CI 0.62 to 0.92) [28].  Oxaliplatin-associated toxicity includes neutropenia, 
diarrhea, and sensory neuropathy [27].  
 Irinotecan, a topoisomerase I inhibitor, is another cytotoxic agent now regularly 
used for the treatment of advanced colorectal cancer.  The combination of infusional 5-
FU/LV with irinotecan (FOLFIRI) is now more commonly used than bolus 5-FU/LV 
with irinotecan (IFL) because of more favorable toxicity data.  The addition of irinotecan 
has been shown to improve progression-free survival in patients with advanced colorectal 
cancer.   In one study, 683 patients were randomized to receive either IFL, bolus 5-
FU/LV alone, or irinotecan alone.  When compared with the group receiving bolus 5-
FU/LV alone, patients treated with the IFL combination demonstrated a 40% 
improvement in median progression-free survival (7.0 months vs. 4.3 months, p=0.004) 
as well as better overall survival (14.8 vs. 12.6 months, p=0.04) [29].  This combination 
was synergistic, as patients receiving irinotecan alone had median survival comparable to 
patients receiving only bolus 5-FU/LV.  A second study randomized 387 patients with 
metastatic colorectal cancer to receive either FOLFIRI or infusional 5-FU/LV alone.  The 
FOLFIRI arm demonstrated significantly longer median time to progression (6.7 vs. 4.4 
months, p<0.001) and better overall survival (17.4 vs. 14.1 months, p=0.031) [30].  The 
most commonly reported toxic effect of irinotecan in both studies was diarrhea, which 
can be severe [29, 30]. 
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 Several randomized trials have directly compared the efficacy of oxaliplatin and 
irinotecan in patients with advanced colorectal cancer.  These studies are summarized in 
Table 1.  Goldberg et al. randomized 795 patients to receive either IFL, FOLFOX, or 
irinotecan and oxaliplatin (IROX).  Patients receiving FOLFOX had a median overall 
survival of 19.5 months, compared to 17.4 months in the IFL group (p=0.0001) and 17.4 
months in the IROX group (p=0.09).  Those in the FOLFOX arm also benefited from 
increased response rates and longer time to progression [31].  Unfortunately, it is difficult 
to draw useful conclusions based on these results because 5-FU/LV was administered in 
different schedules.  Two other studies, however, randomized patients to receive either 
FOLFOX or FOLFIRI, both of which use infusional 5-FU/LV [32, 33].  In both, there 
was no significant difference in response rate, time to progression or overall survival 
between the two study arms (see Table 1).  Finally, Tournigand et al designed a unique 
study to evaluate both FOLFOX and FOLFIRI as first- and second-line therapies in 
advanced colorectal cancer.  In this study, patients randomized to the first arm received 
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FOLFIRI until either disease progression or prohibitive toxicity, at which point patients 
were switched to FOLFOX.  Patients randomized to the second arm received the opposite 
sequence.  Again, there was no significant difference between the two regimens.  
FOLFIRI as first line therapy resulted in response rates of 56% with median progression 
free survival of 8.5 months, which compared with 54% and 8.0 months when FOLFOX 
was given first line [34].  Toxicity profiles were fairly similar between the two agents in 
all four studies. 
 These trials suggest that there is no significant survival advantage between 
FOLFIRI and FOLFOX in patients with metastatic colorectal cancer.  In a recent 
consensus statement, Bartlett et al. conclude that “treatment decisions for first-line 
therapy can be made based on the toxicity profile of individual drugs or on personal 
preference but not because of significant differences in efficacy” [35].  While oxaliplatin 
and irinotecan have comparable effects in advanced colorectal cancer, it is interesting to 
note that FOLFIRI has been significantly less effective than FOLFOX in patients with 
more localized stage III disease, although it is unclear why this is the case [35]. 
 The four-drug combination of oxaliplatin, irinotecan, and infusional 5FU/LV 
(FOLFOXIRI) has also been evaluated in metastatic colorectal cancer.  In a phase III trial 
by Souglakos et al., patients randomized to receive FOLFOXIRI had slightly better 
response rates, time to disease progression and overall survival compared to patients 
treated with FOLFIRI (see Table 1), although this trend was not statistically significant 
[36].  The toxicity profile was significantly worse in the FOLFOXIRI arm, however, with 
much higher rates of grade 3/4 diarrhea and sensory neuropathy (p<.001 for both when 
compared to the FOLFIRI arm).  The authors suggest that sequential treatment with 
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FOLFOX and FOLFIRI (as in the study by Tournigand et al. [34]) may be preferable to 
treatment with FOLFOXIRI, especially when targeted agents are to be added to the 
regimen [36]. 
 
Bevacizumab, cetuximab and panitumumab in advanced colorectal cancer 
 In addition to the cytotoxic agents oxaliplatin and irinotecan, a set of targeted 
agents now have an established role in the treatment of metastatic colorectal cancer.  
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth 
factor (VEGF), which is often expressed by cancer cells seeking to promote angiogenesis.  
Cetuximab and panitumumab are chimerized and fully human monoclonal antibodies, 
respectively, both designed to target the epidermal growth factor receptor (EGFR). 
 Two major randomized phase III trials have evaluated the efficacy of 
bevacizumab in patients with advanced colorectal cancer, one as first-line and the other 
as second-line therapy.  The first, by Hurwitz et al., compares bevacizumab given with 
IFL (n=402) to treatment with IFL plus placebo (n=411).  Bevacizumab significantly 
increased response rates (44.8% vs. 34.8%, p=0.004), progression-free survival (10.6 vs. 
6.2 months, p<0.001) and overall survival (20.3 vs. 15.6 months, p<0.001) [37].  Similar 
results were produced in the second study, which looked at 579 patients previously 
treated with irinotecan-containing regimens.  In this second-line setting, patients 
receiving bevacizumab in combination with FOLFOX had improved overall survival 
compared to patients receiving FOLFOX alone (12.5 vs. 10.7 months, p=0.0024) [38]. 
 There is less data available on the efficacy of cetuximab.  The only completed 
phase III trial randomized patients who had failed prior treatment to receive cetuximab 
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monotherapy or  cetuximab plus irinotecan.  Although patients in the combination arm 
had statistically significant improvement in response rates and median time to 
progression, there was no significant effect on overall survival [39].  With two 
cetuximab-containing arms, it is difficult to draw conclusions on the efficacy of 
cetuximab itself based on these results.  However, multiple phase II studies have 
demonstrated significantly better response rates in patients receiving cetuximab in 
combination with FOLFOX or FOLFIRI [40-42].  These are promising results, but trials 
establishing survival outcomes are still in progress.  The ongoing EPIC trial randomizes 
patients who have failed first-line FOLFOX to receive either cetuximab plus irinotecan or 
irinotecan alone. 
 Recently, panitumumab was also approved for use in advanced colorectal cancer.  
In a phase III randomized trial of 463 patients with progression of disease after standard 
treatment, patients receiving panitumumab monotherapy had a 46% lower tumor 
progression rate compared to patients receiving only supportive care [43].  Ongoing trials 
are currently evaluating panitumumab as first-line treatment in combination with 
FOLFIRI [44] or with FOLFOX and panitumumab (PACCE: Panitumumab Advanced 
Colorectal Cancer Evaluation study) [45].  The most frequently reported adverse event in 
patients treated with panitumumab is a skin rash. 
 Bevacizumab is currently the only targeted therapy with a demonstrated survival 
benefit in the first-line setting, although both cetuximab and panitumumab have shown 
promise and are awaiting results of further investigation.  While these results are pending, 
current standard of care for first-line therapy according to a recent consensus statement is 
either FOLFOX or FOLFIRI in combination with bevacizumab.  If FOLFOX is used 
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first-line, then FOLFIRI should be used as second-line treatment, and vise-versa, and 
cetuximab should be added to the regimen upon progression of disease [35]. 
 
Role of neoadjuvant chemotherapy in patients with colorectal liver metastases  
 The development of these newer therapeutic agents has significantly improved 
prognosis in patients who present with unresectable colorectal liver metastases.  Only a 
decade ago, these patients were typically treated with palliative intent; currently, up to a 
third of patients with initially unresectable hepatic metastases experience enough tumor 
shrinkage to become candidates for surgical resection [15].  In one series, the five-year 
survival rate was 50% in 77 patients who underwent hepatic resections after neoadjuvant 
FOLFOX.  Of the 58 patients who had either R0 or R1 resections, 58% and 50% were 
alive at five and seven years [46].  Five-year survival was 40% in another series of 53 
patients with liver metastases rendered resectable by neoadjuvant FOLFOX [47].  Many 
authors have compared these commendable results to the 28-39% five-year survival rates 
previously reported in resectable patients who underwent primary liver resections [4-10].  
However, it must be noted that five-year survival rates after primary resections are now 
in the range of 50-60% with the adjuvant use of oxaliplatin, irinotecan and targeted 
agents [11, 12].  In a more contemporary analysis, Adam et al. recently looked at a large 
cohort of 1439 consecutive patients treated at a single institution over an 11-year period.  
Survival was 33% at five years and 23% at ten years after secondary hepatic resections 
made possible by systemic chemotherapy, compared to 48% and 30% in primarily 
resected patients (p=0.01).  The lower survival rates in patients who present with initially 
unresectable metastases are not surprising as these patients often have more aggressive 
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and/or widespread disease.  Regardless, patients with secondary hepatic resections now 
have a good chance at long-term disease-free survival (17% at 10 years) [15]. 
 There are no studies evaluating the optimal timing of surgery once unresectable 
colorectal liver metastases become resectable on neoadjuvant chemotherapy.  However, 
current consensus recommends that surgery be scheduled as soon as liver metastases 
become resectable on follow-up imaging [48, 49].  The most compelling concern is that 
prolonged exposure to cytotoxic agents may injure the remnant liver, potentially 
increasing the risk of intraoperative and postoperative complications.  The EORTC 
Intergroup 40983 study is the first prospective randomized trial to examine the extent and 
impact of hepatic injury after neoadjuvant chemotherapy for colorectal liver metastases.  
In this study, patients with potentially resectable metastases were randomized to receive 
six neoadjuvant cycles of FOLFOX-4 or undergo immediate surgical resection.  Patients 
who received FOLFOX were significantly more likely to have sinusoidal lesions (48% 
vs. 11%, p=0.0032) and sinusoidal dilitation (41% vs. 0%, p<0.0001), but not at 
increased risk of steatosis (41% vs. 25%, p=0.26) or steatohepatitis (24% vs. 21%, 
p=NS), the latter two of which have been generally more associated with irinotecan.  
Liver damage did not appear to correlate with surgical complications or outcomes, 
although the authors note that the number of patients with surgical complications (7 of 57 
patients) may have been too low to detect an association [50].  Importantly, this study did 
not address how long chemotherapy was discontinued prior to hepatic resection and 
whether this had an affect on liver toxicity.  Furthermore, everyone in this trial received 6 
cycles of neoadjuvant chemotherapy, so the affect of the duration of neoadjuvant 
chemotherapy can not be determined. Larger prospective studies are needed, as well as 
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investigation of the other chemotherapeutic and biologic agents.  Since VEGF plays a 
role in wound healing, the timing of bevacizumab in particular has been a theoretical 
concern, although again, there is minimal data.  Nevertheless, until more is known, it is 
recommended that bevacizumab be discontinued at least eight weeks prior to hepatic 
resection [35, 51]. 
 While neoadjuvant chemotherapy has a clear role in enhancing resectability of 
liver metastases, its use is less established for patients who present with already 
resectable liver metastases.  Without much evidence either way, some patients may be 
offered immediate surgical resection, while many others are first treated with neoadjuvant 
chemotherapy of varying regimens and duration.  Comparative survival data is needed to 
establish a clear standard, and to perhaps determine whether any factors can predict 
which patients, if any, have better outcomes without neoadjuvant chemotherapy. 
 Only preliminary results are available for ongoing trials evaluating neoadjuvant 
chemotherapy for potentially resectable colorectal liver metastases.  In 2006, the EORTC 
Intergroup provided interim results of their randomized phase III trial comparing 
immediate surgical resection only (no chemotherapy) to six cycles of FOLFOX-4 before 
and after surgery in 364 patients.  Neoadjuvant chemotherapy led to a 30% decrease in 
size of metastatic lesions.  Although more patients in the surgery-only arm made it to the 
operating room (95% vs. 88%), less of these patients were able to undergo complete 
resection (89% vs. 96%).  As a result, there was no significant difference in overall 
resection rate (84% in both arms) [52].  Survival data should be available soon and will 
be crucial to understanding the impact of neoadjuvant chemotherapy.  Unfortunately, 
however, it will be impossible to attribute any survival advantage to the neoadjuvant 
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chemotherapy alone, as postoperative chemotherapy probably also improves survival 
[53].  There are no studies to date which randomize patients with resectable liver 
metastases to receive only adjuvant chemotherapy or both neoadjuvant and adjuvant 
treatment. 
 There are several reasons why neoadjuvant chemotherapy is hypothesized to be 
beneficial even in patients with already resectable colorectal liver metastases.  First, 
tumor reduction by neoadjuvant chemotherapy may allow for smaller, less difficult 
resections, thus helping to limit intraoperative complications and postoperative 
morbidity.  Furthermore, systemic chemotherapy can treat invisible hepatic 
micrometastases as well as subclinical extrahepatic disease before these tumor foci have 
time to grow.  Since patients with known hepatic metastases are at high risk of having 
disease elsewhere, in the liver especially, early systemic chemotherapy would therefore 
be expected to improve long-term survival.  Second, patients often respond better to one 
regimen than another, although this is almost impossible to predict.  It is also difficult to 
assess a regimen’s efficacy in the adjuvant setting after lesions are surgically resected.  A 
neoadjuvant course allows for in vivo assessment of anti-tumor activity and feasibility in 
terms of toxic effects.  In turn, this information can help guide the selection of 
postoperative chemotherapy [51].  Finally, the response or lack of response to 
neoadjuvant chemotherapy may have prognostic value.  Of 131 patients with at least four 
liver metastases in one series, 58 (44%) responded to neoadjuvant chemotherapy, 39 
(30%) had stable disease, and 34 (26%) progressed.  Five-year overall survival after 
hepatic resection was 37% in responders and 30% in patients with stable disease but only 
8% in patients with progression on neoadjuvant chemotherapy (p<0.0001) [54].  In 
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another retrospective analysis, 17 patients with progressive disease on neoadjuvant 
chemotherapy had significantly lower five-year disease specific survival than 29 patients 
who did not progress (38% vs. 87%, p=0.03) [55].  Since all patients in these two series 
underwent resection, it is unclear whether patients who progress on neoadjuvant 
chemotherapy still benefit enough from surgical resection to justify the risk of associated 
morbidity. 
 There are also several theoretical drawbacks to neoadjuvant chemotherapy for 
patients with resectable colorectal liver metastases.  As discussed earlier, liver injury 
from cytotoxic neoadjuvant therapy is worrisome in patients undergoing hepatectomy, 
although this has not yet been shown to affect surgical morbidity and mortality.  Another 
concern is that patients may progress to the point of unresectability while on preoperative 
chemotherapy and miss a window of opportunity for potentially curative resection.  
Fortunately, this has not been the case in the literature.  All patients with resectable 
disease remained resectable in the two retrospective studies described above, even though 
progression while on neoadjuvant chemotherapy did lead to poorer outcomes after liver 
resection [54, 55].  In the prospective EORTC Intergroup 40983 study, preliminary 
results revealed that 7 of 182 patients randomized to receive neoadjuvant chemotherapy 
were not operated due to progression of disease, but this was similar to 5 of 182 patients 
in the surgery-only arm who also progressed to unresectability between randomization 
and surgery [52].  Frequent follow-up evaluation during neoadjuvant treatment and good 
communication between oncologists and surgeons during this critical time are probably 
important factors in maintaining resectable status. 
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 Finally, although counterintuitive, another concern has been that patients may 
respond so well to chemotherapy that one or more colorectal liver metastases can not be 
found at the time of surgery but still harbor radiographically invisible tumor cells.  Two 
small retrospective studies have addressed whether it is safe not to resect the sites of 
previously diagnosed liver metastases which become undetectable after neoadjuvant 
chemotherapy.  In the first study, 9 of 38 patients (24%) with presumed complete 
response were found to have detectable macroscopic disease by inspection, palpation, or 
intraoperative ultrasound.  Of the remaining 29 patients, the sites of original lesions were 
resected in 15 patients and found to harbor microscopic disease in 12 (80%).  At one year 
of follow-up, disease recurred in situ in 11 of 14 patients (79%) who did not have 
resection of the original sites of metastases, although it is not stated whether these 
patients received adjuvant chemotherapy.  In summary, 32 of 38 patients (84%) did not 
have true “cure” despite complete radiographic response to neoadjuvant chemotherapy 
[56].  In the second study, 7 of 15 patients (47%) with complete radiological response 
had macroscopic disease at surgery or postoperative recurrence in situ, while the 
remaining eight patients had no evidence of recurrence at a mean follow-up of three years 
[14].  Results were slightly better in the second series, but there is clearly a considerable 
risk of tumor recurrence when the sites of previously detectable metastases are left 
unresected.  This has led to the recommendation that patients receiving neoadjuvant 
chemotherapy should be re-evaluated frequently and referred for resection before 
achieving complete radiographic response of metastatic lesions, so that all pre-treatment 
sites can be accurately localized and resected [15, 49].  Although this suggestion is 
reasonable given the evidence currently available, it is still possible that patients with 
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such highly responsive tumors may have better outcomes with uninterrupted 
chemotherapy, rather than having treatment suspended for at least several months in 
order to undergo surgical resection. 
 
Neoadjuvant chemotherapy regimens for patients with colorectal liver metastases  
 While research has focused extensively on developing new therapeutic agents and 
increasing the resectability of hepatic colorectal metastases, there have been few studies 
comparing the efficacy of different treatment regimens prior to surgery.   Thus, the 
optimal treatment regimen prior to resection of hepatic colorectal metastases remains 
unclear, as does the appropriate timing of treatment prior to surgery.  Although results are 
pending for trials of neoadjuvant chemotherapy in patients with potentially resectable 
liver metastases [52], all currently available data comes from studies in patients with 
initially unresectable metastases.  In these studies, the proportion of patients converted to 
resectable status is often used as an indication of therapeutic efficacy.  As already 
discussed, definitions of resectability vary from one center to another, making a direct 
comparison of results more difficult.  There are no randomized controlled trials to date 
comparing FOLFOX and FOLFIRI in the neoadjuvant setting, or comparing the efficacy 
of these regimens with and without targeted agents such as bevacizumab.  At least one 
such phase III trial was closed early due to slow patient accrual [57]. 
 The first landmark study demonstrating that neoadjuvant chemotherapy had the 
potential to downstage unresectable colorectal metastases was published by Bismuth and 
colleagues in 1996 [47].  This group continued to follow a large cohort of patients and 
reported updated results in 2001 [58] and most recently in 2004 [15].  As of 2004, 1104 
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patients initially considered unresectable had been treated with chemotherapy, mainly 
consisting of FOLFOX (70%), and another 335 patients with resectable disease had 
undergone primary resections.  Of these, 138 patients (12.5%) were eventually able to 
undergo secondary hepatic resections of colorectal metastases, most of which (93%) were 
R0 resections.  Long-term survival following secondary resection was realized, with 5- 
and 10-year survival rates at 33% and 22%, respectively, although these rates were higher 
in patients who underwent primary resections (48% and 30% respectively, p=0.01).  At a 
mean follow-up of 49 months (range 1-127 months), 111 of 138 patients (80%) had 
relapsed, and median overall survival was 39 months.  Preoperative factors associated 
with worse prognosis included rectal primary, more than two metastatic lesions, 
maximum tumor size >10cm, and CA 19-9 >100 IU/L [15].  This study did not separate 
results according to neoadjuvant regimen, presumably because the majority of patients 
received FOLFOX, although this information would have been helpful. 
 In 1999, Giacchetti et al. performed a retrospective analysis of 151 patients with 
initially unresectable colorectal liver metastases who were treated with oxaliplatin and 
infusional 5-FU/LV.  After a median 5.5 months of treatment, 77 patients underwent liver 
surgery with curative intent, and complete macroscopic resection was achieved in 58 of 
the original 151 patients (38%).  Of these, 42 patients (72%) had recurrent disease and 
median time to progression was 12 months.  Median overall survival had not been 
reached in the subset of 58 patients with complete macroscopic resections, although an 
estimated 5-years survival rate was 58% [46]. 
 As part of Intergroup Study 9741, 795 patients with unresectable colorectal liver 
metastases were randomly assigned to receive IFL (n=264), FOLFOX4 (n=267), or 
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IROX (irinotecan and oxaliplatin, n=265).  Curative resection was achieved in 24 
patients.  With a median postoperative follow-up of 34 months in this subset, median 
time to progression was 18.4 months with 17 patients relapsing and median overall 
survival was 42.4 months.  Of the resected patients, 22 (92%) had received one of the 
oxaliplatin-containing regimens (11 in each of the FOLFOX4 and IROX arms), while 
only 2 patients were treated neoadjuvantly with IFL [59].  Although a direct comparison 
can not be made between IFL and FOLFOX4 because of the different 5-FU 
administration schedules, the increased efficacy of IROX over IFL can only be attributed 
to oxaliplatin. 
 The North Central Cancer Treatment Group also studied the efficacy of 
FOLFOX4 in patients with liver-only metastases that were considered unresectable.  In 
this study, 14 of the 42 patients (33%) treated with FOLFOX4 were able to undergo 
complete R0 resection.  At a median follow-up of 22 months, recurrence rate was similar 
to other studies with 10 patients (71%) having recurrent disease.  Median time to 
recurrence was 19 months and median overall survival had not been reached for the 
subset of resected patients [60]. 
 Two studies published in 2004 evaluated irinotecan-based regimens for treatment 
of unresectable colorectal liver metastases.  In a phase II trial, 40 patients treated with 
FOLFIRI achieved a response rate of 48% and surgical resection was attempted in 16 
patients (40%) who were downsized to the point of resectability.  Of these, 13 patients 
underwent R0 resections.  At a median follow-up of 19 months, all resected patients were 
still alive and median time to progression was 14.3 months (range 2 to 21 months), 
compared to 5.2 months in unresected patients [61].  The second looked retrospectively at 
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56 patients who were able to undergo liver resection after responding to treatment with 
irinotecan-based neoadjuvant chemotherapy.  In this study, the majority of patients were 
treated with FOLFIRI (n=42), while 7 patients also received oxaliplatin and 5 patients 
were treated with irinotecan monotherapy.  R0 resection was achieved in 42 patients 
(75%) and median overall survival was 42 months with tumor recurrence in 41 patients 
(73%) at a median follow-up of 23.1 months [62]. 
   The most important disadvantage to neoadjuvant irinotecan has been its 
association with steatohepatitis.  In a recent study of 406 patients who underwent hepatic 
metastectomy, Vauthey and colleagues demonstrated that 20% of patients who received 
neoadjuvant irinotecan had steatohepatitis compared to only 6% in patients with prior 
oxaliplatin exposure (odds ratio 3.7; 95% CI 1.3 to 10.5, p=0.02).  Unfortunately, 90-day 
mortality rates were significantly higher in patients with steatohepatitis compared to 
patients who did not have steatohepatitis (14.7% vs. 1.6%, odds ratio 10.5, 95% CI 2.0 to 
36.4, p=0.001).  In contrast, although oxaliplatin was associated with sinusoidal injury, 
there was no increased morbidity or mortality when compared to patients who did not 
receive any neoadjuvant chemotherapy [63]. 
 The only study to randomize patients with unresectable colorectal liver metastases 
to either FOLFOX6 or FOLFIRI was published in 2004 by Tournigand and colleagues.  
In this study, patients randomized to the first arm (n=109) received FOLFIRI until either 
disease progression or prohibitive toxicity, at which point patients were switched to 
FOLFOX.  Patients randomized to the second arm (n=111) received the opposite 
sequence.  Response rates were similar; FOLFIRI as first line therapy resulted in 
response rates of 56% with median progression free survival of 8.5 months, which 
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compared with 54% and 8.0 months when FOLFOX was given first line.  Interestingly, 
however, secondary resection was able to be performed in 9% of patients (n=10) after 
just first-line FOLFIRI (mean 12 cycles) compared to 22% of patients (n=24) treated with 
FOLFOX (mean 10 cycles).  This difference was statistically significant (p=0.02), 
suggesting that FOLFOX may have better efficacy in the neoadjuvant setting.  The 
proportion of R0 resections did not reach statistical significance, however, with 8 patients 
in the FOLFIRI arm and 14 in the FOLFOX arm able to undergo R0 resections (p=0.26).  
Only three patients were able to undergo surgical resection after second-line therapy (two 
after receiving FOLFOX second-line, and one after receiving FOLFIRI second-line) [34]. 
 Finally, several studies have assessed the efficacy of FOLFOXIRI in downstaging 
unresectable colorectal liver metastases to the point of resectability.  In one phase III trial, 
9 of 137 patients randomized to FOLFOXIRI were able to undergo secondary R0 
resection of liver metastases, compared to just 2 of 146 patients in the FOLFIRI arm [36].  
A similar phase III trial of 244 patients reported that 14% of patients randomized to 
receive FOLFOXIRI were able to undergo R0 secondary resection, compared to 6% in 
the FOLFIRI arm (p=0.05) [64].  The same group reported a median overall survival of 
36.8 months in a subset of 19 of 74 patients (26%) who were able to undergo curative 
secondary resection after treatment with FOLFOXIRI [65].  Of 24 patients treated with 
FOLFOXIRI in another study, 9 (37.5%) underwent R0 secondary resections [66]. 
 Studies are underway to evaluate the safety and efficacy of bevacizumab as part 
of neoadjuvant treatment for colorectal liver metastases.  The ongoing First BEAT trial 
enrolled 1927 patients with metastatic colorectal cancer, in which all patients were 
treated with bevacizumab in combination with FOLFOX (28%), FOLFIRI (26%), 
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XELOX (17%), or other (29%).  At the time of report, 81 patients were able to undergo 
metastectomy (34 after FOLFOX + bevacizumab, 19 after FOLFIRI + bevacizumab, 20 
after XELOX + bevacizumab).  Bevacizumab was stopped 6-8 weeks (two half-lives) 
prior to surgery and only one patient had wound healing complications which were not 
described in detail and another patient had intra-operative bleeding.  Long-term survival 
data is not yet available [67, 68].  In a retrospective study assessing surgical complication 
rates in patients treated with neoadjuvant bevacizumab, the use of bevacizumab did not 
increase wound healing complications (28% vs. 24% in patients not treated with 
neoadjuvant bevacizumab, p=0.66), and the interval from bevacizumab to surgery also 
did not affect wound healing complications (p=0.71) [69].  Although it has been shown 
that bevacizumab increases response rates and survival in combination with IFL [37] or 
FOLFOX [38], neither study provided results for subsequent resection rate. 
 In summary, while new treatments for metastatic colorectal cancer continue to be 
developed, the ideal neoadjuvant regimen prior to resection of liver metastases is still 
unknown.  The best neoadjuvant regimen should combine a high response rate with the 
lowest peri-operative complication rate.  Some evidence supports the use of oxaliplatin-
based regimens over those containing irinotecan, although completed randomized studies 
are lacking.  Treatment with irinotecan has been shown to have increased incidence of 
steatohepatitis with associated operative morbidity, making oxaliplatin a more attractive 
choice in the neoadjuvant setting.  Bevacizumab has also shown promise in the 
neoadjuvant setting, although many surgeons are still cautious due to the theoretical risk 
of wound-healing complications.  The use of neoadjuvant chemotherapy in the setting of 
initially resectable metastases is even less established. 
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PURPOSE, HYPOTHESIS AND SPECIFIC AIMS 
 In light of this uncertainty, the present study was designed to determine which 
neoadjuvant chemotherapy regimens, specifically oxaliplatin-based vs. irinotecan-based, 
led to most successful outcomes after resection of colorectal liver metastases at Yale-
New Haven Hospital in recent years.  I hypothesized that oxaliplatin-based neoadjuvant 
chemotherapy would lead to better disease-free survival after surgical resection of 
colorectal liver metastases. 
 The primary aim for this study was to determine which neoadjuvant 
chemotherapy regimens lead to most successful resection of colorectal cancer metastases 
to the liver, measured in terms of disease-free survival outcomes.  The secondary aim was 
to determine whether any of the following factors were associated with disease 
recurrence:  primary tumor site, timing of liver metastases, number of liver metastases, 
neoadjuvant chemotherapy regimen, use of targeted biological agents, treatment duration, 
treatment response, time from chemotherapy to liver resection and treatment with 
adjuvant chemotherapy. 
 
METHODS 
 A retrospective chart review was performed of all patients who underwent liver 
resection of colorectal cancer metastases at Yale-New Haven Hospital between January 
2003 and December 2005.  January 2004 was initially chosen as the starting date for this 
study, as this was the date FOLFOX was approved for first-line treatment of metastatic 
colorectal cancer.  However, this resulted in too few patients for analysis, so inclusion 
was expanded to January 2003.  No patients were excluded from the study.  All liver 
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resections were performed by the same hepatobiliary surgeon.  Patient records were 
evaluated for patient characteristics (age, sex, race), initial diagnosis (location, histology, 
stage, lymph node involvement, vascular invasion, metastases, tumor marker levels), 
initial treatment (adjuvant chemotherapy, radiation), recurrence / metastases (location, 
sites, number and location in liver, lymph node involvement), treatment regimen(s) prior 
to resection of hepatic metastases, results of surgical liver resection (complete or partial 
resection, histopathology), adjuvant treatment after liver resection and post-operative 
disease recurrence and survival.  This retrospective study was approved by the Yale 
Humans Investigation Committee. 
 Synchronous metastases were defined as metastases diagnosed before or at the 
same time as the primary cancer, or within 6 months of diagnosis of the primary cancer.  
Radiographic response was categorized according to Response Evaluation Criteria in 
Solid Tumors (RECIST) guidelines.  R0 resection was defined as complete tumor 
removal including negative histological removals, R1 resection was defined as positive 
microscopic margins, and R2 resection was defined as positive gross margins.  All 
patients were taken to the operating room with curative intent with the goal of R0 
resection. 
 All statistical analysis was performed with MedCalc software version 9.3.0 
(MedCalc Software, Mariakerke, Belgium).  Calculations of median disease-free survival 
and actuarial 3-year disease-free survival rates were based on survival curves drawn 
according to Kaplan-Meier methods.  The log-rank test was used to compare the survival 
curves of four neoadjuvant treatment groups.  Trends in neoadjuvant treatment choices 
over time were assessed using Chi-squared analysis. 
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RESULTS 
 Twenty-seven patients underwent resection of colorectal liver metastases at Yale-
New Haven Hospital between January 2003 and December 2005 (Table 2).  The mean 
age of patients at the time of liver resection was 56.9 years (range 38 to 76 years), and the 
majority of patients (17, 63%) were male.  Most patients had colon adenocarcinoma 
primary lesions (17, 63%), although 8 patients had rectal primaries and 2 had junctional 
primaries.  About half of the patients (14, 52%) presented with synchronous liver 
metastases.  Of the 13 patients with metachronous liver metastases, all had been treated 
with adjuvant chemotherapy after resection of the primary tumor, except for the two 
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patients with Stage II disease.  Median time from diagnosis of colorectal primary to 
resection of liver metastases was 9.6 months in patients with synchronous metastases 
(range 4 to 31 months), 27.6 months in patients with metachronous metastases (range 9 
months to 7 years), and 19.2 months in all patients.  Sixteen patients presented with only 
one metastastic focus in the liver, and the rest had either two or three foci on imaging 
except for one patient with five.  None of the patients had known extrahepatic metastases. 
 Almost all patients in this study had resectable colorectal liver metastases at the 
time of initial presentation.  Only patient #14, with a single liver metastasis impinging on 
the right and middle hepatic veins as well as the main portal vein, was considered 
unresectable at initial presentation.  This patient was rendered resectable after a complete 
radiologic and ultimately histologic response to neoadjuvant FOLFOX and bevacizumab.  
 Neoadjuvant chemotherapy regimens varied from patient to patient.  Six patients 
did not receive any neoadjuvant chemotherapy; each of these six patients had a single 
metachronous metastatic lesion in the liver and one patient had been offered neoadjuvant 
FOLFOX but refused.  One patient (patient #10), diagnosed with three liver metastases 
on postoperative imaging immediately after abdomino-perineal resection of a rectal 
primary, was treated with adjuvant 5-FU as a chemosensitizer for local radiotherapy.  
This patient received no other systemic chemotherapy and was therefore categorized as 
not receiving any neoadjuvant treatment for this analysis. 
 The most common neoadjuvant regimen was FOLFOX, given as first-line 
neoadjuvant chemotherapy to 14 patients.  Four of these patients were treated with 
FOLFOX in combination with bevacizumab.  Of the 14 patients initially treated with 
FOLFOX, 10 patients experienced a partial response (71%, included all 4 patients 
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receiving bevacizumab), one patient had stable disease, two patients had progressive 
disease and were switched to FOLFIRI (patient #19 and patient #21), and another patient 
was switched to FOLFIRI because of an allergic reaction (patient #18).  The 11 patients 
treated only with first-line neoadjuvant FOLFOX received an average of 9 cycles prior to 
liver resection (range 5 to 14 cycles). 
 The remaining six patients were all treated with first-line irinotecan-based 
regimens.  Four patients received an average of 8 cycles of FOLFIRI (range 3 to 12 
cycles), one patient received several cycles of IFL, and another was treated with ten 
months of irinotecan in combination with capecitabine (Xeloda).  One patient (patient 
#22) had progressive disease after a 6-week course of FOLFIRI, so chemotherapy was 
discontinued and the patient was referred for liver resection.  Two other patients had 
stable disease: one after FOLFIRI and the other after irinotecan in combination with 
capecitabine.  Information on the clinical response to treatment was not available for the 
other three patients treated with irinotecan-based first-line regimens. 
 During the three years studied, 2003 through 2005, there were some trends in the 
use of neoadjuvant chemotherapy in patients who underwent liver resection of colorectal 
metastases.  In 2003, of 8 patients who underwent liver resection, all with initially 
resectable disease, only half received neoadjuvant chemotherapy (2 with FOLFOX, 1 
with FOLFIRI and 1 with IFL) while the other half had immediate liver resection.  By 
2005, of 11 patients who underwent liver resection for initially resectable colorectal 
metastases, only one patient did not receive neoadjuvant chemotherapy.  Eight of the 
remaining 10 patients (80%) who underwent liver resection in 2005 were treated with 
neoadjuvant FOLFOX first-line, compared to just 2 patients (20%) treated with first-line 
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FOLFIRI.  This trend did not reach statistical significance, however (p=0.08 by Chi-
squared analysis). 
 All patients underwent R0 resections, except for patient #9, who underwent R2 
resection with gross positive margins after right hepatic trisegmentectomy (liver 
segments 4,5,6,7,8).  Two patients, both treated with combination FOLFOX and 
bevacizumab, had complete histological response with no viable tumor cells seen on 
histology.  One patient (patient #24) died on post-operative day 33 after hemoperitoneum 
from splenic capsule tear during hepatectomy.  This patient did not receive any 
neoadjuvant chemotherapy or targeted treatment.  There were no other incidents of post-
operative mortality; thus, the overall mortality rate in this study group of 27 patients was 
3.7% 
 
Figure 1. Kaplan-Meier disease-free survival curve for all patients with >1 year 
of follow-up after hepatic resection of colorectal metastases (n=15) 
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 Outcome data (>1 year) could be obtained for 15 of the 26 patients who survived 
hepatic resection.  Of the 11 patients lost to follow-up, two had moved out-of-state, and 
nine had local private oncologists who could not be reached for follow-up data.  At a 
median follow-up of 25.0 months (range 13 to 44 months), 6 of 15 patients (40%) had no 
evidence of recurrent disease while 9 patients (60%) had relapsed.  Median time to 
recurrence was 11.1 months (range 5 to 17 months).  Five patients (33%) had recurrent 
disease in the liver (three of whom also had extra-hepatic disease), two patients (13%) 
had lung metastases, and two patients (13%) had anastomotic recurrence in the colon.  
The Kaplan-Meier disease-free survival curve for all 15 patients with follow-up data is 
shown in Figure 1.  Median disease-free survival was 16.3 months, actual 1-year disease-
free survival was 67% and actuarial 3-year disease-free survival was 39%.  One patient 
with extensive disease recurrence in the liver, lungs and retroperitoneum died 12 months 
after liver resection.  The other 14 patients were alive at most recent follow-up; therefore, 
the overall actual 1-year survival rate for patients with outcome data was 93%. 
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 Outcome data for each type of neoadjuvant chemotherapy regimen is presented in 
Table 3.  Out of the 15 patients with follow-up, six were treated with neoadjuvant 
FOLFOX prior to liver resection, three with first-line FOLFOX followed by second-line 
FOLFIRI, two with FOLFIRI, one with IFL, and three patients had no neoadjuvant 
chemotherapy.  The Kaplan-Meier disease-free survival curves according to neoadjuvant 
treatment group are shown in Figure 2.  Median disease-free survival was 15.5 months in 
patients treated with neoadjuvant FOLFOX, 16.3 months in patients treated with first-line 
FOLFOX followed by second-line FOLFIRI, also 16.3 months in patients treated with 
irinotecan-based neoadjuvant therapy, and was not reached in the group who did not 
receive any neoadjuvant treatment (p=0.84 by log-rank test).  Actual 1-year disease-free 
survival rate was 67% regardless of neoadjuvant treatment group.  Median time to 
recurrence after liver resection was 12.2 months in patients treated with FOLFOX (10, 
11, 13 and 17 months), 11.4 months in patients treated with first-line FOLFOX followed 
by second-line FOLFIRI (6 and 16 months), 5 months in the patient who relapsed after 
FOLFIRI, 16 months in the patient who relapsed after IFL, and 11 months in the patient 
who relapsed after no neoadjuvant chemotherapy. 
 The sample size was too small to determine which factors were associated with 
disease recurrence.  Out of the 15 patients with follow-up, all three patients treated with 
bevacizumab had recurrent disease (Table 2).  Otherwise, the study lacked the statistical 
power to detect whether outcome was associated with primary tumor site, timing of liver 
metastases, number of liver metastases, neoadjuvant chemotherapy regimen, treatment 
duration, treatment response, time from chemotherapy to liver resection, or treatment 
with adjuvant chemotherapy. 
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Figure 2. Kaplan-Meier estimates of disease-free survival according to 
neoadjuvant chemotherapy regimen 
 
 
 
  
DISCUSSION 
 This retrospective study compares the efficacy of oxaliplatin- and irinotecan-
based neoadjuvant chemotherapy regimens in patients who underwent liver resection of 
colorectal metastases at Yale-New Haven Hospital between 2003 and 2005.  Only 
patients who underwent liver resection were included.  Patients who never achieved 
resectable status despite systemic chemotherapy were not accounted for in this study.  
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Therefore, almost all patients in the present study had resectable disease at initial 
presentation.  This is in contrast to the currently available literature, which almost 
exclusively focuses on neoadjuvant chemotherapy for unresectable liver metastases. 
 The majority of patients undergoing liver resection of colorectal metastases at 
Yale-New Haven Hospital in recent years were treated with neoadjuvant FOLFOX.  This 
may either represent the local preferences of medical oncologists or be a reflection of the 
literature, which has shown a bias towards neoadjuvant FOLFOX over irinotecan-based 
regimens.  This bias is supported by the observation that neoadjuvant irinotecan has been 
associated with steatohepatitis and increased surgical morbidity and mortality [63].  
Chemotherapy-induced liver toxicity was not noted in the present study, although the 
sample size was small. 
 Also notable was the evolving trend towards the use of neoadjuvant 
chemotherapy in patients with already resectable colorectal liver metastases.  The 
percentage of these patients receiving neoadjuvant chemotherapy increased from 50% in 
2003 to 87% by 2005, perhaps associated with the increased availability of FOLFOX and 
FOLFIRI after 2003.  As there are still no clear recommendations for the use of 
neoadjuvant chemotherapy in patients with resectable disease, it would be interesting to 
know whether this is a more widespread trend.  Prospective studies are needed to 
establish clear recommendations.  Survival data should be available soon from the 
EORTC Intergroup study, a randomized phase III trial comparing immediate surgical 
resection to neoadjuvant and adjuvant FOLFOX [52]. 
 Unfortunately, there were not enough patients in the study to adequately compare 
oxaliplatin- and irinotecan-based neoadjuvant chemotherapy regimens for patients 
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undergoing resection of colorectal liver metastases.  With outcome data on 15 patients, 
disease recurrence, time to recurrence, and one-year disease-free survival was almost 
identical among patients receiving FOLFOX, irinotecan-based regimens, or first-line 
FOLFOX followed by second-line FOLFIRI.  Although all three patients with follow-up 
data who received bevacizumab eventually had recurrent disease, this is unlikely to be a 
real finding given the low patient number.  This study also lacked the statistical power to 
determine which patient, tumor, and treatment factors were associated with recurrence of 
disease. 
 As with any retrospective study, there are some drawbacks to this study design.  
Many biases can be introduced when treatment providers, patients and the person 
collecting data know which treatment regimen is being used.  Furthermore, follow-up 
data could not be obtained for all patients.  This study only emphasizes the need for 
prospective trials comparing oxaliplatin- and irinotecan-based neoadjuvant chemotherapy 
regimens for patients with either resectable or unresectable colorectal hepatic metastases.  
Future translational research should also focus on determining whether tumor molecular 
profiling can be used to more accurately tailor treatment decisions to each individual 
patient. 
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